Cannabis and CBD for Mood Disorders: What the Evidence Actually Shows
Cannabis may provide short-term relief for some mood-related symptoms, but current evidence does not show that cannabis or CBD is an established treatment for depression or bipolar disorder. The strongest findings come from small observational studies and app-based self-reports—not randomized clinical trials designed to determine whether cannabis treats a mood disorder over time.
Mood disorders include conditions such as major depression and bipolar disorder. They can involve persistent sadness, hopelessness, guilt, loss of interest, changes in sleep or appetite, low energy, difficulty concentrating, and—in some cases—mania or suicidal thoughts. Causes are complex and may include genetic vulnerability, brain biology, stress, trauma, medical conditions, and substance use. Johns Hopkins Medicine provides an overview of mood-disorder symptoms, causes, and treatments.
Standard treatment depends on the diagnosis. It may include psychotherapy, antidepressants, mood stabilizers, family therapy, or, for treatment-resistant depression, brain-stimulation treatments such as electroconvulsive therapy. People should not replace prescribed medication or therapy with cannabis without discussing the decision with a qualified clinician.
What the bipolar-disorder study found
A 2016 pilot study published in PLOS ONE examined mood and cognitive performance among 12 people with bipolar disorder who smoked marijuana, 18 people with bipolar disorder who did not, 23 marijuana users without another major psychiatric disorder, and 21 healthy controls.
Among the participants with bipolar disorder who used marijuana, mood ratings improved within four hours of smoking. The researchers also found no additional cognitive impairment compared with the nonsmoking bipolar group. However, the study was small, participants were regular users who were not randomly assigned to receive cannabis, and it did not establish whether cannabis improved the long-term course of bipolar disorder. The authors described the findings as preliminary and called for larger, longer studies.
That distinction matters. A temporary change in self-reported mood is not the same as treating bipolar depression or preventing future manic, depressive, or mixed episodes. In addition, later research has associated cannabis use disorder with a higher risk of psychotic bipolar disorder, although observational research cannot by itself prove that cannabis caused the condition. A 2023 JAMA Psychiatry study examined this association.
Evidence from the Releaf app
Another frequently cited study, published in 2020, analyzed 5,876 cannabis-use sessions recorded by 1,819 people through the Releaf App. Users reported an immediate reduction in the intensity of depressive feelings after consuming cannabis flower. Products with higher labeled THC concentrations were more strongly associated with short-term symptom relief, while CBD concentrations were generally not associated with greater relief.
The study is useful for documenting how people experience cannabis in real-world settings, but it cannot show that cannabis works as an antidepressant. Participants selected whether and how much cannabis to use, there was no placebo comparison, the data were self-reported, and the researchers did not randomly assign treatment. The study also recorded unwanted effects: some users reported feeling unmotivated or experiencing other effects that could worsen low mood. The full paper is available as “The Effectiveness of Cannabis Flower for Immediate Relief from Symptoms of Depression”.
What does CBD add?
CBD is different from THC, the psychoactive component primarily responsible for the cannabis “high.” The available evidence for CBD in mood disorders is limited and should not be generalized from studies of cannabis flower. In particular, the Releaf study found that CBD levels were generally unrelated to immediate changes in depressive-symptom intensity.
A 2020 systematic review in BMC Psychiatry reported potentially encouraging findings across several psychiatric conditions, but it also emphasized the small number and low quality of many studies. The review did not establish cannabis as a proven treatment for depression, bipolar disorder, anxiety, psychosis, or ADHD.
Where the evidence stands now
A larger systematic review and meta-analysis published in The Lancet Psychiatry in 2026 found insufficient evidence to determine whether cannabinoids treat bipolar disorder. It also found no randomized trials testing cannabinoid efficacy for depression as the primary condition. Across the psychiatric conditions studied, cannabinoids were associated with more overall adverse events than placebo. The review’s findings are available from the journal.
For now, cannabis and CBD are best viewed as unproven options for mood disorders rather than established alternatives to antidepressants, mood stabilizers, or psychotherapy. THC may produce brief symptom relief for some people, but it can also cause anxiety, sedation, impaired memory, dependence, or worsening psychiatric symptoms. Anyone with bipolar disorder, a history of psychosis, suicidal thoughts, or substance-use problems should discuss cannabis use with a mental-health professional before using it.
If mood symptoms are persistent, severe, or accompanied by thoughts of self-harm, professional care is important. A proper diagnosis and evidence-based treatment plan remain the safest route to lasting improvement.
